Synergistic inhibitory effects of curcumin and 5-fluorouracil on the growth of the human colon cancer cell line HT-29

Chemotherapy

Volumn 52, Issue 1, 2005, Pages 23-28

  Du, Boyu ^a   Jiang, Liping ^a   Xia, Quan ^a   Zhong, Laifu ^a  

^a DALIAN MEDICAL UNIVERSITY   (China)

Author keywords

5 Fluorouracil; Colon cancer; Combination treatment; COX 2; Curcumin; Synergistic effect

Indexed keywords

CURCUMIN; CYCLOOXYGENASE 2; FLUOROURACIL;

ARTICLE; CANCER CELL CULTURE; CANCER GROWTH; CELL PROLIFERATION; COLON CARCINOMA; CONTROLLED STUDY; EVALUATION; HUMAN; HUMAN CELL; IC 50; PRIORITY JOURNAL; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; WESTERN BLOTTING;

CELL PROLIFERATION; COLONIC NEOPLASMS; CURCUMIN; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITORS; DRUG SYNERGISM; FLUOROURACIL; GENE EXPRESSION REGULATION, NEOPLASTIC; HT29 CELLS; HUMANS;

EID: 29344455140     PISSN: 00093157     EISSN: None     Source Type: Journal    
DOI: 10.1159/000090238     Document Type: Article

References (37)

1. Parker SL, Tong T, Bolden S, Wingo PA: Cancer Statistics 1996. CA Cancer J Clin 1996;46:5-27.
2. Jessup JM, McGinnis LS, Winchester DP, Eyre H, Fremgen A, Murphy GP, Menck HR: Clinical highlights from the National Cancer Data Base: 1996. CA Cancer J Clin 1996;46:185-192.
3. Tsujii M, Kawano S, DuBois RN: Cyclooxygenase-2 expression in human colon cancer cells increases metastatic potential. Proc Natl Acad Sci USA 1997;94:3336-3340.
4. Tsujii M, DuBois RN: Alterations in cellular adhesion and apoptosis in epithelial cells overexpressing prostaglandin endoperoxide synthase 2. Cell 1995;83:493-501.
5. Sun Y, Tang XM, Half E, Kuo MT, Sinicrope FA: Cyclooxygenase-2 overexpression reduces apoptotic susceptibility by inhibiting the cytochrome c-dependent apoptotic pathway in human colon cancer cells. Cancer Res 2002;62:6323-6328.
6. Hoetelmans RW, Vahrmeijer AL, Mulder GJ, van de Velde CJ, Nagelkerke JF, van Dierendonck JH: Bcl-2 overexpression does not prevent but retards Adriamycin toxicity in CC531 colon carcinoma cells. Chemotherapy 2003;49:309-315.
7. Kargman SL, O'Neill GP, Vickers PJ, Evans JF, Mancini JA, Jothy S: Expression of prostaglandin G/H synthase-1 and -2 protein in human colon cancer. Cancer Res 1995;55:2556-2559.
8. Eberhart CE, Coffey RJ, Radhika A, Giardiello FM, Ferrenbach S, DuBois RN: Up-regulation of cyclooxygenase-2 gene expression in human colorectal adenomas and adenocarcinomas. Gastroenterology 1994;107:1183-1188.
9. Koki AT, Leahy KM, Masferrer JL: Potential utility of COX-2 inhibitors in chemoprevention and chemotherapy. Expert Opin Investig Drugs 1999;8:1623-1638.
10. 3H]curcumin. Toxicology 1981-82;22:337-344.
11. Huang MT, Newmark HL, Frenkel K: Inhibitory effects of curcumin on tumorigenesis in mice. J Cell Biochem 1997;27(suppl):26-34.
12. Chuang SE, Kuo ML, Hsu CH, Chen CR, Lin JK, Lai GM, Hsieh CY, Cheng AL: Curcumin-containing diet inhibits diethylnitrosamine-induced murine hepatocarcinogenesis. Carcinogenesis 2000;21:331-335.
13. Chung SE, Cheng AL, Lin JK, Kuo ML: Inhibition by curcumin of diethylnitrosamine-induced hepatic hyperplasia, inflammation, cellular gene products and cell-cycle-related proteins in rats. Food Chem Toxicol 2000;38:991-995.
14. Goel A, Boland CR, Chauhan DP: Specific inhibition of cyclooxygenase-2 (COX-2) expression by dietary curcumin in HT-29 human colon cancer cells. Cancer Lett 2001;172:111-118.
15. Cheng AL, Hsu CH, Lin JK, Hsu MM, Ho YF, Shen TS, Ko JY, Lin JT, Lin BR, Ming-Shiang W, Yu HS, Jee SH, Chen GS, Chen TM, Chen CA, Lai MK, Pu YS, Pan MH, Wang YJ, Tsai CC, Hsieh CY: Phase I clinical trial of curcumin, a chemopreventive agent in patients with high-risk or pre-malignant lesions. Anticancer Res 2001;21:2895-2900.
16. Kelloff GJ, Crowell JA, Hawk ET, Steele VE, Lubet RA, Boone CW, Covey JM, Doody LA, Omenn GS, Greenwald P, Hong WK, Parkinson DR, Bagheri D, Baxter GT, Blunden M, Doeltz MK, Eisenhauer KM, Johnson K, Knapp GG, Longfellow DG, Malone WF, Nayfield SG, Seifried HE, Swall LM, Sigman CC: Strategy and planning for chemopreventive drug development clinical development plans II. J Cell Biochem Suppl 1996;26:54-71.
17. Chou TC, Talalay P: Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul 1984;22:27-55.
18. Chou TC, Motzer RJ, Tong Y, Bosl GJ: Computerized quantitation of synergism and antagonism of Taxol, topotecan and cisplatin against human teratocarcinoma cell growth: a rational approach to clinical protocol design. J Natl Cancer Inst 1994;86:1517-1524.
19. Khafif A, Schantz SP, Chou TC, Edelstein D, Sacks PG: Quantitation of chemopreventive synergism between (-)-epigallocatechin-3-gallate and curcumin in normal, premalignant and malignant human oral epithelial cells. Carcinogenesis 1998;19:419-424.
20. Mans DR, Grivicich I, Peters GJ, Schwartsmann G: Sequence-dependent growth inhibition and DNA damage formation by the irinotecan-5-fluorouracil combination in human colon carcinoma cell lines. Eur J Cancer 1999;35:1851-1861.
21. Wiebke EA, Grieshop NA, Loehrer PJ, Eckert GJ, Sidner RA: Antitumor effects of 5-fluorouracil on human colon cancer cell lines: antagonism by levamisole. J Surg Res 2003;111:63-69.
22. Soriano AF, Helfrich B, Chan DC, Heasley LE, Bunn PA Jr, Chou TC: Synergistic effects of new chemopreventive agents and conventional cytotoxic agents against human lung cancer cell lines. Cancer Res 1999;59:6178-6184.
23. Hida T, Kozaki K, Muramatsu H, Masuda A, Shimizu S, Mitsudomi T, Sugiura T, Ogawa M, Takahashi T: Cyclooxygenase-2 inhibitor induces apoptosis and enhances cytotoxicity of various anticancer agents in non-small cell lung cancer cell lines. Clin Cancer Res 2000;6:2006-2011.
24. Subongkot S, Frame D, Leslie W, Drajer D: Selective cyclooxygenase-2 inhibition: a target in cancer prevention and treatment. Pharmacotherapy 2003;23:9-28.
25. Bombardier C, Laine L, Reicin A, Shapiro D, Burgos-Vargas R, Davis B, Day R, Ferraz MB, Hawkey CJ, Hochberg MC, Kvien TK, Schnitzer TJ; VIGOR Study Group: Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group. N Engl J Med 2000;343:1520-1528.
26. Solomon SD, McMurray JJ, Pfeffer MA, Wittes J, Fowler R, Finn P, Anderson WF, Zauber A, Hawk E, Bertagnolli M: Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention. N Engl J Med 2005;352:1071-1080.
27. Nussmeier NA, Whelton AA, Brown MT, Langford RM, Hoeft A, Parlow JL, Boyce SW, Verburg KM: Complications of the COX-2 inhibitors parecoxib and valdecoxib after cardiac surgery. N Engl J Med 2005;352:1081-1091.
28. Chainani-Wu N: Safety and anti-inflammatory activity of curcumin: a component of tumeric (Curcuma longa). J Altern Complement Med 2003;9:161-168.
29. Thiyagarajan M, Sharma SS: Neuroprotective effect of curcumin in middle cerebral artery occlusion induced focal cerebral ischemia in rats. Life Sci 2004;74:969-985.
30. Nirmala C, Puvanakrishnan R: Protective role of curcumin against isoproterenol induced myocardial infarction in rats. Mol Cell Biochem 1996;159:85-93.
31. Nirmala C, Puvanakrishnan R: Effect of curcumin on certain lysosomal hydrolases in isoproterenol-induced myocardial infarction in rats. Biochem Pharmacol 1996;51:47-51.
32. 2+ signaling. Biochem Pharmacol 1999;58:1167-1172.
33. Ragnhammar P, Hafstrom L, Nygren P, Glimelius B, SBU-group: Swedish Council of Technology Assessment in Health Care. A systematic overview of chemotherapy effects in colorectal cancer. Acta Oncol 2001;40:282-308.
34. Barutca S, Ceyhan C, Meydan N, Ozturk B, Tekten T, Onbasili A, Kadikoylu G, Bolaman Z: A new perspective on cardiotoxicity of 5-fluorouracil. A novel research tool 'cardiac ultrasonic integrated backscatter analysis' indicates transient, subclinical myocardial dysfunction due to high-dose leucovorin and infusional 5-fluorouracil regimen. Chemotherapy 2004;50:113-118.
35. Chuang SE, Yeh PY, Lu YS, Lai GM, Liao CM, Gao M, Cheng AL: Basal levels and patterns of anticancer drug-induced activation of nuclear factor-κB (NF-κB), and its attenuation by tamoxifen, dexamethasone, and curcumin in carcinoma cells. Biochem Pharmacol 2002;63:1709-1716.
36. Lim JW, Kim H, Kim KH: Nuclear factor-κB regulates cyclooxygenase-2 expression and cell proliferation in human gastric cancer cells. Lab Invest 2001;81:349-360.
37. Plummer SM, Hill KA, Festing MF, Steward WP, Gescher AJ, Sharma RA: Clinical development of leukocyte cyclooxygenase 2 activity as a systemic biomarker for cancer chemopreventive agents. Cancer Epidemiol Biomarkers Prev 2001;10:1295-1299.